Ibrutinib First-Line CLL/SLL: Efficacy & Risk Factors
- A new analysis of real-world data indicates that cytogenetic risk factors do not impact survival rates for chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) patients treated...
- Researchers examined data from 1,242 CLL/SLL patients who received single-agent ibrutinib as a first-line treatment between 2011 and 2023.
- The study, which investigated the role of ibrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), found no statistically important difference in real-world overall survival...
New research demonstrates that ibrutinib plays a crucial role in treating chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), unaffected by cytogenetic risk factors. The study, analyzing real-world data from over a thousand patients, reinforces ibrutinib’s efficacy as a first-line treatment option. High-risk patients showed similar survival outcomes, supporting ibrutinib’s consistent performance. This crucial data, brought to you by News Directory 3, highlights the drug’s enduring impact, including the vital analysis presented. Learn more about how ibrutinib continues to redefine treatment strategies for CLL/SLL. Discover what’s next …
Ibrutinib’s Role in CLL/SLL Survival Unaffected by Risk Factors
Updated June 13, 2025
A new analysis of real-world data indicates that cytogenetic risk factors do not impact survival rates for chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) patients treated with first-line ibrutinib. The findings support the continued use of ibrutinib as an initial therapy for these patients.
Researchers examined data from 1,242 CLL/SLL patients who received single-agent ibrutinib as a first-line treatment between 2011 and 2023. Of these, 969 were classified as high-risk, while 273 were not. High-risk features included del(17p) in 32.9% of patients, del(11q) in 36.7%, and unmutated IGHV in 58.7%. The average age was about 70 years, with a median follow-up around 31-32 months.
The study, which investigated the role of ibrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), found no statistically important difference in real-world overall survival (rwOS) between the high-risk and non-high-risk groups. The hazard ratio was 1.09 (95% CI, 0.79, 1.51; P = .60).
According to the authors, “Results show that patients with high-risk CLL/SLL treated with first-line single-agent ibrutinib had similar rwOS compared to patients with non-high-risk disease.”
A seperate analysis excluding